Researchers discover how TBI can lead to Alzheimer’s disease and chronic traumatic encephalopathy
New research led by investigators at Beth Israel Deaconess Medical Center (BIDMC) provides the first direct evidence linking traumatic brain injury to Alzheimer’s disease and chronic traumatic encephalopathy (CTE) — and offers the potential for early intervention to prevent the development of these debilitating neurodegenerative diseases.
TBI can result from repetitive contact sport injuries or from exposure to military blasts, and is one of the most significant risk factors for both Alzheimer’s disease and CTE.
In a study published today in the online edition of the journal Nature, the researchers found that a misshapen isoform of the tau protein can develop as soon as 12 hours after TBI, setting in motion a destructive course of events that can lead to widespread neurodegeneration. Importantly, the researchers have developed a potent antibody that can selectively detect and destroy this highly toxic protein.
“TBI is a leading cause of death and disability in children and young adults and also affects approximately 20 percent of the more than two million troops who have deployed to Iraq and Afghanistan,” said co-senior author Kun Ping Lu, MD, PhD, Chief of the Division of Translational Therapeutics in the Department of Medicine at BIDMC and Professor of Medicine at Harvard Medical School (HMS). “Our study shows that an early neurodegenerative process induced by the toxic tau protein can begin just hours after a traumatic brain injury. In both cell models of stress and in mouse models simulating sport- and military-related TBI, the production of this pathogenic protein, called cis P-tau, disrupts normal neurological functioning, spreads to other neurons and leads to widespread neuronal death. We have developed a potent monoclonal antibody that can prevent the onset of widespread neurodegeneration by identifying and neutralizing this toxic protein and restoring neurons’ structural and functional abilities.”
Alzheimer’s disease is the most common form of dementia in older individuals and currently affects more than 5 million Americans and 30 million people worldwide. Chronic traumatic encephalopathy is a degenerative brain disease associated with a number of neurological symptoms including risk-taking, aggression and depression. CTE can also lead to progressive dementia.
Previous research has shown that abnormal phosphorylation of the tau protein underlies Alzheimer’s and other neurodegenerative diseases. In recent years, the Lu laboratory discovered that tau exists in two isoforms, or shapes –¬ ¬¬one functioning and one disease-causing.
“Healthy tau protein is found in the brain and serves to assemble and support microtubules, the ‘scaffolding systems’ that give neurons their unique shape and are integral to memory and normal brain functioning,” explained Lu. But in Alzheimer’s, CTE and other neurodegenerative diseases, collectively called tauopathies, tau becomes tangled and unable to function properly.
“Recent studies of CTE in the brains of boxers, American football players and blast-exposed veterans have identified extensive neurofibrillary tau tangles,” he said. “But, because these tangles were not detected until months or, more likely, years after TBI, it has not been known whether tauopathy is a cause or a consequence of TBI-related neurodegenerative disease. We have now shown that it is a cause of these diseases.”
The Latest on: Neurodegeneration antibody
[google_news title=”” keyword=”Neurodegeneration antibody” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Neurodegeneration antibody
- The Antibody Initiative Antivenomon May 10, 2024 at 9:08 pm
Antivenom (often spelled “antivenin”) is an antibody product that can disable a particular venom’s toxins. If injected quickly after a bite or sting, the antibodies in antivenom neutralize the venom, ...
- Acumen Pharmaceuticals Doses First Patient in Early Alzheimer's Drug Trialon May 10, 2024 at 6:46 am
In the ALTITUDE-AD trial, researchers will measure patients' disease progression on various Alzheimer's scales and track changes in amyloid and tau biomarkers.
- What is the association between cytokines and autoimmune diseases?on May 3, 2024 at 8:01 am
Under normal conditions, cytokines aid in pathogen recognition and elimination while contributing to immune system homeostasis. When the immune system malfunctions, irregularities in cytokine ...
- Study identifies potential strategy to diminish the devastating impacts of traumatic brain injurieson April 22, 2024 at 5:51 am
For the roughly 1.5 million Americans per year who survive a traumatic brain injury, health outcomes vary widely.
- Mobilizing Microglia in the Fight Against Alzheimer’s Diseaseon April 17, 2024 at 5:00 pm
Clinical trials are also underway for antibodies that activate microglia by targeting TREM2. This growing body of research underscores the potential for leveraging microglia in effective short-term ...
- Acumen and Lonza to produce Alzheimer’s drug sabirnetugon April 14, 2024 at 9:41 am
A humanised monoclonal antibody, sabirnetug targets and neutralises ... and continuous driver of the synaptic dysfunction and neurodegeneration associated with AD, sabirnetug represents a ...
- Monoclonal Antibodies in Rheumatoid Arthritison April 11, 2024 at 5:00 pm
No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).
- p-Tau217 Immunotherapy Alleviates Tangle Pathology in Miceon April 11, 2024 at 9:44 am
In the March 20 Neuron, they reported that tauopathy mice given an antibody, dubbed mAb2A7, against p-Tau217 had fewer tangles, less neurodegeneration, and better memory and motor function. Their ...
- Harnessing the therapeutic potential of naturally occurring human antibodieson July 5, 2023 at 5:18 am
“We have developed a powerful platform technology to rapidly identify and characterize naturally occurring human antibodies, and our current focus is on allergies and neurodegeneration,” said ...
- Renaissance In Precision Neuroscience Expectedon October 3, 2022 at 6:59 am
Opinions expressed by Forbes Contributors are their own. I write and teach about innovation in healthcare. This week saw considerable optimism and promise for neuroscience research. The ...
via Bing News